BIOPHYTIS, a biopharma company specializing in drugs to treat age-related diseases, has entered into an agreement with Patheon for the industrial scale-up and manufacture of clinical batches for a Phase IIB trial for drug candidate Macuneos in AMD (age-related macular degeneration).   Macuneos is a drug candidate against the dry form of AMD, which affects the central part of the retina, called the macula, causing severe visual impairment and irreversible loss of central vision. Macuneos works ...